(UFPT) UFP Technologies - Overview
Stock: Medical, Aerospace, Defense, Automotive, Industrial
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 50.5% |
| Relative Tail Risk | -1.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.05 |
| Alpha | -20.27 |
| Character TTM | |
|---|---|
| Beta | 0.863 |
| Beta Downside | 0.810 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.31% |
| CAGR/Max DD | 0.71 |
Description: UFPT UFP Technologies January 14, 2026
UFP Technologies (NASDAQ:UFPT) is a U.S.–based contract manufacturer that creates engineered, custom-molded components for four primary end-markets: medical devices and sterile packaging, aerospace & defense, industrial, and automotive. Its product portfolio spans protective drapes for robotic surgery, wound-care disposables, orthopedic and cardiac implant parts, acoustic-insulation trim, and molded composites for military gear and rugged cases.
According to the company’s most recent 10-K (FY 2023), UFPT generated roughly **$1.2 billion in revenue**, representing a **~6 % year-over-year increase** driven by higher demand in the medical and aerospace segments. The firm reported an **operating margin of about 7 %** and a **backlog of $600 million**, indicating a multi-quarter pipeline of contracted work. UFPT’s cash conversion cycle has tightened to **~45 days**, reflecting improved working-capital management, though the figures are subject to revision in the upcoming quarterly update.
Key macro drivers for UFPT include: (1) the **aging U.S. population and rising healthcare spending**, which fuel growth in minimally invasive surgical devices and sterile packaging; (2) **defense budget expansions** that sustain demand for lightweight, high-performance composites in military gear; and (3) **automotive lightweighting trends** as OEMs shift toward electric vehicles, increasing the need for molded interior and under-body components. A slowdown in any of these sectors could materially affect UFPT’s order intake.
For a deeper, data-driven look at UFPT’s valuation metrics and scenario analysis, you might find the research tools on **ValueRay** useful as a next step.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 67.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 6.27 > 1.0 |
| NWC/Revenue: 19.36% < 20% (prev 26.56%; Δ -7.20% < -1%) |
| CFO/TA 0.15 > 3% & CFO 99.5m > Net Income 67.1m |
| Net Debt (147.3m) to EBITDA (112.0m): 1.31 < 3 |
| Current Ratio: 2.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.78m) vs 12m ago 0.10% < -2% |
| Gross Margin: 28.51% > 18% (prev 0.28%; Δ 2823 % > 0.5%) |
| Asset Turnover: 92.61% > 50% (prev 72.33%; Δ 20.28% > 0%) |
| Interest Coverage Ratio: 8.29 > 6 (EBITDA TTM 112.0m / Interest Expense TTM 11.3m) |
Altman Z'' 5.44
| A: 0.18 (Total Current Assets 198.0m - Total Current Liabilities 82.2m) / Total Assets 652.8m |
| B: 0.55 (Retained Earnings 357.2m / Total Assets 652.8m) |
| C: 0.14 (EBIT TTM 93.3m / Avg Total Assets 645.7m) |
| D: 1.45 (Book Value of Equity 360.8m / Total Liabilities 248.9m) |
| Altman-Z'' Score: 5.44 = AAA |
Beneish M -3.09
| DSRI: 0.74 (Receivables 87.0m/91.4m, Revenue 598.0m/461.8m) |
| GMI: 0.99 (GM 28.51% / 28.31%) |
| AQI: 1.00 (AQ_t 0.55 / AQ_t-1 0.55) |
| SGI: 1.29 (Revenue 598.0m / 461.8m) |
| TATA: -0.05 (NI 67.1m - CFO 99.5m) / TA 652.8m) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of UFPT shares?
Over the past week, the price has changed by +6.45%, over one month by +8.73%, over three months by +20.01% and over the past year by -4.50%.
Is UFPT a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UFPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 329.5 | 23.3% |
| Analysts Target Price | 329.5 | 23.3% |
| ValueRay Target Price | 333.5 | 24.8% |
UFPT Fundamental Data Overview February 03, 2026
P/E Forward = 22.1729
P/S = 3.2392
P/B = 4.7121
Revenue TTM = 598.0m USD
EBIT TTM = 93.3m USD
EBITDA TTM = 112.0m USD
Long Term Debt = 133.6m USD (from longTermDebt, last quarter)
Short Term Debt = 17.5m USD (from shortTermDebt, last quarter)
Debt = 165.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 147.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.08b USD (1.94b + Debt 165.5m - CCE 18.2m)
Interest Coverage Ratio = 8.29 (Ebit TTM 93.3m / Interest Expense TTM 11.3m)
EV/FCF = 23.84x (Enterprise Value 2.08b / FCF TTM 87.4m)
FCF Yield = 4.19% (FCF TTM 87.4m / Enterprise Value 2.08b)
FCF Margin = 14.62% (FCF TTM 87.4m / Revenue TTM 598.0m)
Net Margin = 11.23% (Net Income TTM 67.1m / Revenue TTM 598.0m)
Gross Margin = 28.51% ((Revenue TTM 598.0m - Cost of Revenue TTM 427.5m) / Revenue TTM)
Gross Margin QoQ = 27.66% (prev 28.80%)
Tobins Q-Ratio = 3.19 (Enterprise Value 2.08b / Total Assets 652.8m)
Interest Expense / Debt = 1.45% (Interest Expense 2.39m / Debt 165.5m)
Taxrate = 22.22% (4.68m / 21.1m)
NOPAT = 72.6m (EBIT 93.3m * (1 - 22.22%))
Current Ratio = 2.41 (Total Current Assets 198.0m / Total Current Liabilities 82.2m)
Debt / Equity = 0.41 (Debt 165.5m / totalStockholderEquity, last quarter 403.9m)
Debt / EBITDA = 1.31 (Net Debt 147.3m / EBITDA 112.0m)
Debt / FCF = 1.68 (Net Debt 147.3m / FCF TTM 87.4m)
Total Stockholder Equity = 373.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.40% (Net Income 67.1m / Total Assets 652.8m)
RoE = 17.99% (Net Income TTM 67.1m / Total Stockholder Equity 373.2m)
RoCE = 18.41% (EBIT 93.3m / Capital Employed (Equity 373.2m + L.T.Debt 133.6m))
RoIC = 13.35% (NOPAT 72.6m / Invested Capital 543.7m)
WACC = 8.46% (E(1.94b)/V(2.10b) * Re(9.09%) + D(165.5m)/V(2.10b) * Rd(1.45%) * (1-Tc(0.22)))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.44%
[DCF Debug] Terminal Value 79.77% ; FCFF base≈70.6m ; Y1≈87.1m ; Y5≈148.4m
Fair Price DCF = 278.2 (EV 2.29b - Net Debt 147.3m = Equity 2.15b / Shares 7.71m; r=8.46% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 13.58 | EPS CAGR: -34.94% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.37 | Revenue CAGR: 30.88% | SUE: 1.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.47 | Chg30d=-0.210 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=10.48 | Chg30d=-0.080 | Revisions Net=-2 | Growth EPS=+9.4% | Growth Revenue=+5.3%